Autophagy as a target for anticancer therapy

By F. Janku, D. McConkey, D. Hong, Razelle Kurzrock. Nature Reviews Clinical Oncology, 2011

797 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? (2022, background): “GTP-Ras suppresses autophagy via activating PI3KCI and the RAF/MEK/ ERK pathway (58).”
Autophagy in malignant transformation and cancer progression (2015, positive): “In line with this notion, autophagy-deficient tumors are often more sensitive to several chemotherapeutic agents as well as to radiation therapy than their autophagy-proficient counterparts (Janku et al , 2011; Ko et al , 2014; Levy et al , 2014).”
Ageing as a risk factor for disease. (2012, background): “Chemotherapy drug combinations that include autophagy inhibitors have shown promise in pre-clinical trials and animal models [114,115].”
Autophagy: Renovation of Cells and Tissues (2011, background): “Given the role of autophagy in tumor progression, autophagy suppression could be a strategy for cancer treatment (Amaravadi et al., 2011; Janku et al., 2011).”
p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. (2014, background): “depending on the cell type and strength of specific stimuli [10– 12].”